Morepen Laboratories: 70% Montelukast Share, 31x P/E – API King or Generic Gamble?

At a Glance

Morepen Laboratories is the underdog pharma player with a crown in APIs, leading the market with monstrous shares in Montelukast (70%) and Loratadine (69%). Yet, Q1 FY26 wasn’t a blockbuster – profits crashed 70% YoY and revenue slipped 6.6%. The stock trades at a P/E of 31.5x, which is like paying for a Cipla experience at a generic store.

Introduction

Once a household name for home diagnostic kits, Morepen today plays the API chessboard, supplying to big pharma while dabbling in branded formulations. The stock had a dream run in COVID times (thanks to testing kits), but since then, investors are left asking – “Doctor, is this stock healthy?” With FY25 revenue flatlining and margins stuck at 8–10%, it’s a pharma drama worth diagnosing.

Business Model (WTF Do They Even Do?)

• APIs: Breadwinner with market leadership in anti-asthma and anti-allergy drugs.
• Branded Formulations: Generics, OTC products – smaller revenue chunk.
• Home Health Devices: Glucometers, BP monitors – stable but low growth.

Roast: They sell the raw material for your pills and the device to check if you need more pills. Genius.

Financials Overview

Comment: Revenue grows like homeopathy medicine – slow and doubtful.

Valuation

• P/E: 31.5x – not cheap for a small-cap API player.
• EV/EBITDA: Moderate, but pricing pressure looms.